BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime Sells 20,000 Shares

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime sold 20,000 shares of the business’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the transaction, the director now owns 474,994 shares in the company, valued at $43,347,952.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

• On Tuesday, March 5th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $85.51, for a total transaction of $85,510.00.
• On Tuesday, February 27th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.35, for a total transaction of $90,350.00.
• On Friday, February 9th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $88.28, for a total transaction of $1,324,200.00.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $90.47 on Thursday. BioMarin Pharmaceutical Inc. has a one year low of $76.02 and a one year high of $100.31. The firm has a market capitalization of $17.07 billion, a price-to-earnings ratio of 102.81, a PEG ratio of 1.69 and a beta of 0.31. The company’s fifty day moving average price is $87.57 and its 200-day moving average price is $89.11. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.51 and a quick ratio of 1.57.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The company had revenue of $646.21 million during the quarter, compared to analysts’ expectations of $639.53 million. During the same quarter in the prior year, the company earned $0.11 EPS. The firm’s revenue was up 20.2% on a year-over-year basis. On average, equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 1.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the company. Cannon Global Investment Management LLC boosted its position in BioMarin Pharmaceutical by 11.4% during the 1st quarter. Cannon Global Investment Management LLC now owns 7,800 shares of the biotechnology company’s stock valued at $681,000 after buying an additional 800 shares during the period. New England Research & Management Inc. purchased a new stake in BioMarin Pharmaceutical during the 1st quarter valued at $1,341,000. Capital Insight Partners LLC purchased a new stake in BioMarin Pharmaceutical during the 1st quarter valued at $209,000. Gateway Investment Advisers LLC lifted its position in shares of BioMarin Pharmaceutical by 65.2% in the 1st quarter. Gateway Investment Advisers LLC now owns 21,320 shares of the biotechnology company’s stock worth $1,862,000 after purchasing an additional 8,415 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth about $5,119,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BMRN. Stifel Nicolaus reissued a “buy” rating and issued a $101.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, December 21st. Canaccord Genuity Group reissued a “hold” rating and issued a $91.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, February 29th. Royal Bank of Canada reissued a “sector perform” rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Robert W. Baird lowered their price target on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $107.61.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.